The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Immuno-oncology approaches in MDS
Naval Daver, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, explores the use of immuno-oncology in myelodysplastic syndromes (MDS), including targeted therapies such as IDH inhibitors, FLT3 inhibitors, venetoclax targeting BCL-2, as well as the anti-TIM-3 checkpoint sabatolimab evaluated in a Phase III study with azacitidine in patients with MDS (NCT03066648). Dr Daver highlights these agents as a promising future for the treatment and management of patients with myelodysplastic syndromes, and points towards the tumor microenvironment as an important area of understanding for the implementation of immunotherapies and as a factor determining resistance or lack of response to therapeutic agents. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
